$BPTH
BIO-PATH HOLDINGS, INC.

2024 Q2 Form 10-Q Financial Statement

#000155837024008135 Filed on May 14, 2024

View on sec.gov

Income Statement

Concept 2024 Q2 2024 Q1
Revenue $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $1.165M $1.407M
YoY Change -2.18% 7.98%
% of Gross Profit
Research & Development $1.873M $2.288M
YoY Change -38.61% -42.64%
% of Gross Profit
Depreciation & Amortization $28.00K $22.00K
YoY Change 27.27% 0.0%
% of Gross Profit
Operating Expenses $3.038M $3.695M
YoY Change -28.38% -30.18%
Operating Profit -$3.038M -$3.695M
YoY Change -28.38% -30.18%
Interest Expense $6.000K $0.00
YoY Change -25.0% -100.0%
% of Operating Profit
Other Income/Expense, Net $1.169M $538.0K
YoY Change 14512.5% 2731.58%
Pretax Income -$1.869M -$3.157M
YoY Change -55.86% -40.13%
Income Tax
% Of Pretax Income
Net Earnings -$1.869M -$3.157M
YoY Change -55.86% -40.13%
Net Earnings / Revenue
Basic Earnings Per Share -$1.16 -$4.88
Diluted Earnings Per Share -$1.16 -$4.88
COMMON SHARES
Basic Shares Outstanding 1.656M 678.8K
Diluted Shares Outstanding 1.612M 647.0K

Balance Sheet

Concept 2024 Q2 2024 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $4.006M $188.0K
YoY Change 16.32% -97.21%
Cash & Equivalents $4.006M $188.0K
Short-Term Investments
Other Short-Term Assets $700.0K $800.0K
YoY Change -59.91% -51.92%
Inventory
Prepaid Expenses $274.0K $632.0K
Receivables
Other Receivables
Total Short-Term Assets $5.019M $1.637M
YoY Change -19.81% -84.83%
LONG-TERM ASSETS
Property, Plant & Equipment $48.00K $54.00K
YoY Change -57.89% -60.29%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $99.00K $131.0K
YoY Change -62.64% -57.88%
TOTAL ASSETS
Total Short-Term Assets $5.019M $1.637M
Total Long-Term Assets $99.00K $131.0K
Total Assets $5.118M $1.768M
YoY Change -21.55% -84.07%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $800.0K $1.700M
YoY Change 25.39% 105.56%
Accrued Expenses $2.200M $2.000M
YoY Change 225.93% 105.55%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $3.010M $3.812M
YoY Change 111.08% 99.58%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $817.0K $581.0K
YoY Change 1385.45% 583.53%
Total Long-Term Liabilities $817.0K $581.0K
YoY Change 1385.45% 583.53%
TOTAL LIABILITIES
Total Short-Term Liabilities $3.010M $3.812M
Total Long-Term Liabilities $817.0K $581.0K
Total Liabilities $3.827M $4.393M
YoY Change 158.41% 120.2%
SHAREHOLDERS EQUITY
Retained Earnings -$112.6M -$110.8M
YoY Change 11.48% 14.42%
Common Stock $2.000K $1.000K
YoY Change -75.0% -87.5%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $1.300M -$2.600M
YoY Change
Total Liabilities & Shareholders Equity $5.118M $1.768M
YoY Change -21.55% -84.07%

Cashflow Statement

Concept 2024 Q2 2024 Q1
OPERATING ACTIVITIES
Net Income -$1.869M -$3.157M
YoY Change -55.86% -40.13%
Depreciation, Depletion And Amortization $28.00K $22.00K
YoY Change 27.27% 0.0%
Cash From Operating Activities -$4.266M -$1.038M
YoY Change 29.78% -71.58%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 7.220M 174.0K
YoY Change
NET CHANGE
Cash From Operating Activities -4.266M -1.038M
Cash From Investing Activities
Cash From Financing Activities 7.220M 174.0K
Net Change In Cash 2.954M -864.0K
YoY Change -189.87% -76.35%
FREE CASH FLOW
Cash From Operating Activities -$4.266M -$1.038M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2024Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
647000
CY2023Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
398000
CY2024Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001133818
CY2024Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2024Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
CY2024Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2024Q1 dei Amendment Flag
AmendmentFlag
false
CY2024Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2024Q1 dei Entity Registrant Name
EntityRegistrantName
BIO-PATH HOLDINGS INC
CY2024Q1 us-gaap Preferred Stock Value
PreferredStockValue
CY2023Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
398000
CY2024Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
754000
CY2024Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-4.88
CY2023Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-13.25
CY2024Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
753795
CY2024Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2024Q1 dei Document Type
DocumentType
10-Q
CY2024Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2024Q1 dei Document Period End Date
DocumentPeriodEndDate
2024-03-31
CY2024Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2024Q1 dei Entity File Number
EntityFileNumber
001-36333
CY2024Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2024Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
87-0652870
CY2024Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
4710 Bellaire Boulevard, Suite 210
CY2024Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
Bellaire
CY2024Q1 dei Entity Address State Or Province
EntityAddressStateOrProvince
TX
CY2024Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
77401
CY2024Q1 dei City Area Code
CityAreaCode
832
CY2024Q1 dei Local Phone Number
LocalPhoneNumber
742-1357
CY2024Q1 dei Security12b Title
Security12bTitle
Common Stock, par value $0.001 per share
CY2024Q1 dei Trading Symbol
TradingSymbol
BPTH
CY2024Q1 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2024Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2024Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2024Q1 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2024Q1 dei Entity Small Business
EntitySmallBusiness
true
CY2024Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2024Q1 dei Entity Shell Company
EntityShellCompany
false
CY2024Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
1656235
CY2024Q1 us-gaap Cash
Cash
188000
CY2023Q4 us-gaap Cash
Cash
1052000
CY2024Q1 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
632000
CY2023Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
632000
CY2024Q1 us-gaap Other Assets Current
OtherAssetsCurrent
817000
CY2023Q4 us-gaap Other Assets Current
OtherAssetsCurrent
1358000
CY2024Q1 us-gaap Assets Current
AssetsCurrent
1637000
CY2023Q4 us-gaap Assets Current
AssetsCurrent
3042000
CY2024Q1 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
1120000
CY2023Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
1120000
CY2024Q1 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
1066000
CY2023Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
1044000
CY2024Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
54000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
76000
CY2024Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
77000
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
102000
CY2024Q1 us-gaap Assets
Assets
1768000
CY2023Q4 us-gaap Assets
Assets
3220000
CY2024Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
1746000
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
457000
CY2024Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1984000
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1346000
CY2024Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
82000
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
103000
CY2024Q1 us-gaap Liabilities Current
LiabilitiesCurrent
3812000
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
1906000
CY2024Q1 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
578000
CY2023Q4 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
863000
CY2024Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
3000
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
10000
CY2024Q1 us-gaap Liabilities
Liabilities
4393000
CY2023Q4 us-gaap Liabilities
Liabilities
2779000
CY2024Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2024Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2024Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2024Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2024Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2024Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
754000
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
398000
CY2024Q1 us-gaap Common Stock Value
CommonStockValue
1000
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
1000
CY2024Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
108138000
CY2023Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
108047000
CY2024Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-110764000
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-107607000
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
-2625000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
441000
CY2024Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
1768000
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
3220000
CY2024Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2288000
CY2023Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3989000
CY2024Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1407000
CY2023Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1303000
CY2024Q1 us-gaap Operating Expenses
OperatingExpenses
3695000
CY2023Q1 us-gaap Operating Expenses
OperatingExpenses
5292000
CY2024Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-3695000
CY2023Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-5292000
CY2024Q1 bpth Period Changes In Fair Value Of Warrant Liability
PeriodChangesInFairValueOfWarrantLiability
-538000
CY2023Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
19000
CY2024Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
538000
CY2023Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
19000
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-3157000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-5273000
CY2024Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-4.88
CY2023Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-13.25
CY2024Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
647000
CY2023Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
398000
CY2024Q1 us-gaap Profit Loss
ProfitLoss
-3157000
CY2023Q1 us-gaap Profit Loss
ProfitLoss
-5273000
CY2024Q1 us-gaap Share Based Compensation
ShareBasedCompensation
170000
CY2023Q1 us-gaap Share Based Compensation
ShareBasedCompensation
206000
CY2024Q1 us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
25000
CY2023Q1 us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
23000
CY2024Q1 us-gaap Depreciation
Depreciation
22000
CY2023Q1 us-gaap Depreciation
Depreciation
22000
CY2024Q1 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-538000
CY2023Q1 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-1191000
CY2024Q1 us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
-541000
CY2023Q1 us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
20000
CY2024Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
1927000
CY2023Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
224000
CY2024Q1 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-28000
CY2023Q1 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-26000
CY2024Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-1038000
CY2023Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-3653000
CY2024Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
174000
CY2024Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
174000
CY2024Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-864000
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-3653000
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
1052000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
10384000
CY2024Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
188000
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
6731000
CY2023Q1 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
85000
CY2022Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
14174000
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
206000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-5273000
CY2023Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
9107000
CY2023Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
441000
CY2024Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
-79000
CY2024Q1 us-gaap Other Assets Current
OtherAssetsCurrent
800000
CY2023Q4 us-gaap Other Assets Current
OtherAssetsCurrent
1400000
CY2024Q1 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
170000
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-3157000
CY2024Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-2625000
CY2024Q1 us-gaap Cash
Cash
200000
CY2024Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
1700000
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
500000
CY2024Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2000000.0
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1300000
CY2024Q1 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
578000
CY2023Q4 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
863000
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
-2600000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
400000
CY2024Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
753795
CY2024Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2024Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
700000
CY2024Q1 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false
CY2024Q1 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2024Q1 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2024Q1 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false

Files In Submission

Name View Source Status
0001558370-24-008135-index-headers.html Edgar Link pending
0001558370-24-008135-index.html Edgar Link pending
0001558370-24-008135.txt Edgar Link pending
0001558370-24-008135-xbrl.zip Edgar Link pending
bpth-20240331.xsd Edgar Link pending
bpth-20240331x10q.htm Edgar Link pending
bpth-20240331x10q_htm.xml Edgar Link completed
bpth-20240331xex31.htm Edgar Link pending
bpth-20240331xex32.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
bpth-20240331_cal.xml Edgar Link unprocessable
bpth-20240331_def.xml Edgar Link unprocessable
bpth-20240331_lab.xml Edgar Link unprocessable
bpth-20240331_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable